Included in the formulation
АТХ:S.01.E.D.51 Timolol in combination with other drugs
Pharmacodynamics:Tafluprost
The fluorinated analogue of prostaglandin F2α, a selective agonist of FP-receptors. Increases the outflow of moisture along the uveoscleral pathway, reducing intraocular pressure. The effect of the drug begins 3-4 hours after the injection, the maximum effect develops after 8-12 hours. Duration of action is 24 hours.
Timolol
Non-selective blocker of β-adrenergic receptors. When instillation into the conjunctival sac, it inhibits the adenylate cyclase ciliary system, which carries sodium ions from the blood into the intraocular fluid, which leads to a decrease in intraocular pressure.
Does not affect the refraction, accommodation and the size of the pupil.
Pharmacokinetics:Tafluprost
Free penetrates through the cornea, hydrolyzed to a biologically active form. The maximum concentration in aqueous humor occurs 2 hours after topical application.
The half-life is 17 minutes.
Timolol
After instillation into the conjunctival sac, the therapeutic effect develops in 1-2 hours and lasts for 8-24 hours.
Absorption into the total blood flow is insignificant, the drug does not have a systemic effect.
Indications:It is used for the treatment of glaucoma, it is used for acute increase in ophthalmotonus.
VII.H40-H42.H40.1 Primary open angle glaucoma
VII.H40-H42.H40.0 Suspicion of glaucoma
Contraindications:Age to 18 years, corneal dystrophy, bronchial asthma, atrophic rhinitis, sinus bradycardia, severe heart failure, individual intolerance.
Carefully:Pregnancy and lactation, aphakia, pseudo-aphakia. Congenital, inflammatory, neovascular forms of glaucoma. Diabetes mellitus, thyrotoxicosis, myasthenia gravis, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:1 drop once a day in a conjunctival sac at night.
Side effects:Eye irritation: itching, sensation of foreign body, congestion hyperemia. Increased pigmentation of the iris, macular edema, blurred vision.
Allergic reactions.
Overdose:Hyperemia of the eyes and eyelids.
Treatment is symptomatic.
Interaction:Mydriasum with simultaneous application with epinephrine.
Special instructions:Before using the drug, the patient should be warned about irreversible changes in eye color, darkening of the eyelid skin, changes in thickness, length and number of eyelashes. Especially if one eye is treated.
Persons using contact eye correction are recommended to wear the lenses not earlier than 15 minutes after instillation.
During drug treatment it is not recommended to drive vehicles and work with moving mechanisms.